English
French
Press Release
|
07 |
Dec 2022 |
IntelGenx Announces Collaboration with UPEI to Evaluate Acceptance and Preference of VetaFilm™ Platform in Dogs and Ca... |
|
22 |
Nov 2022 |
IntelGenx Receives FDA PDUFA Date for RIZAFILM®... |
|
10 |
Nov 2022 |
IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor... |
|
10 |
Nov 2022 |
IntelGenx Reports Third Quarter 2022 Financial Results... |
|
09 |
Nov 2022 |
IntelGenx Enters into Feasibility & Development Agreement For CBD-Infused VetaFilm™... |
|
03 |
Nov 2022 |
IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow... |
|
02 |
Nov 2022 |
IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Ac... |
|
25 |
Oct 2022 |
IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film... |
|
20 |
Oct 2022 |
IntelGenx Announces Issuance of New U.S. Patent Covering VersaFilm® Technology... |
|
18 |
Oct 2022 |
IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®... |
|
13 |
Oct 2022 |
IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an ... |
|
08 |
Sep 2022 |
IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Pa... |
|
11 |
Aug 2022 |
IntelGenx Reports Second Quarter 2022 Financial Results... |
|
04 |
Aug 2022 |
IntelGenx to Report Second Quarter 2022 Financial Results on August 11, 2022 – Conference Call to Follow... |
|
05 |
Jul 2022 |
IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures... |
|
01 |
Jun 2022 |
IntelGenx Announces Intention to Issue Shares in Payment of Principal and Interest on Outstanding Debentures... |
|
12 |
May 2022 |
IntelGenx Reports First Quarter 2022 Financial Results... |
|
10 |
May 2022 |
IntelGenx Announces Voting Results on Election of Directors and other items... |
|
05 |
May 2022 |
IntelGenx to Report First Quarter 2022 Financial Results on May 12, 2022 – Conference Call to Follow... |
|
26 |
Apr 2022 |
IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference... |
|
24 |
Mar 2022 |
IntelGenx Reports Fourth Quarter and Full-Year 2021 Financial Results... |
|
17 |
Mar 2022 |
IntelGenx to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 – Conference Call to Follow... |
|
01 |
Feb 2022 |
IntelGenx Receives Third Loan Tranche from atai... |
|
20 |
Jan 2022 |
First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients wit... |